Last reviewed · How we verify
Nimotuzumab plus S1
At a glance
| Generic name | Nimotuzumab plus S1 |
|---|---|
| Also known as | Taixinsheng，Tegafur Gimeracil Oteracil Potassium Capsule |
| Sponsor | Chinese PLA General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial (PHASE2)
- Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age (PHASE2)
- Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma (PHASE2)
- SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer (PHASE2)
- A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer (PHASE2)
- Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma (PHASE2)
- EGFR Monoclonal Antibody for Advanced Gastric Cancer (PHASE2)
- Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nimotuzumab plus S1 CI brief — competitive landscape report
- Nimotuzumab plus S1 updates RSS · CI watch RSS
- Chinese PLA General Hospital portfolio CI